HSP90AA1 and prostate carcinoma: In PC3-MM2 prostate cancer cells, HSP90 C-terminal inhibitors, such as KU-135 and novobiocin, disrupted the HSP90α/Aha1 complex, leading to inhibited cell migration, which is a critical factor in tumor metastasis [183].